Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Systemic lupus erythematosus and lupus nephritis

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Drug sales for SLE in the seven major markets in terms of market value and volume in 2012 and 2022 (estimated).

References

  1. Koutsokeras, T. & Healy, T. PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis — Global Drug Forecast and Market Analysis to 2022 (GlobalData, 2013).

    Google Scholar 

  2. Lateef, A. & Petri, M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res. Ther. 14, S4 (2012).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Toli Koutsokeras or Tina Healy.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Koutsokeras, T., Healy, T. Systemic lupus erythematosus and lupus nephritis. Nat Rev Drug Discov 13, 173–174 (2014). https://doi.org/10.1038/nrd4227

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4227

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing